Principle and design of clinical efficacy observation of extracorporeal cardiac shock wave therapy for patients with myocardial ischemia-reperfusion injury: A prospective randomized controlled trial protocol

• Published in: PloS one Vol. 18; no. 12; p. e0294060
• Main Authors: Li, Xianbin, Zhang, Chaoyue, Liu, Changzhi, Ma, Yiming, Shi, Yunke, Ye, Yujia, Ma, Xuejuan, Liu, Yixi, Luo, Xiang, Lin, Fanru, Wang, Jincheng, Tao, Jifa, Lun, Jinping, Cai, Hongyan, Hu, Zhao
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 08.12.2023; Public Library of Science (PLoS)
• Subjects: Angina; Angina pectoris; Angioplasty; Arrhythmia; Cardiac patients; Cardiovascular disease; Cardiovascular diseases; Care and treatment; Cells (biology); Cerebral infarction; Clinical trials; Complications and side effects; Congestive heart failure; Coronary artery bypass; Coronary artery disease; Coronary vessels; Death; Drug therapy; Electrocardiography; Health services; Heart attack; Heart attacks; Heart diseases; Heart failure; Informed consent; Injuries; Ischemia; Lithotripsy; Medical imaging; Medical prognosis; Medical research; Medicine, Experimental; Myocardial infarction; Myocardial ischemia; Patients; Progenitor cells; Prognosis; Quality of life; Reperfusion; Reperfusion injury; Segments; Shear stress; Shock; Shock waves; Signal transduction; Structure-function relationships; Testing; China; Japan
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0294060

Acute ST-segment elevation myocardial infarction (STEMI) remains a serious life threatening event with a poor prognosis due to myocardial ischemia/reperfusion injury despite coronary revascularization. Extracorporeal cardiac shock wave (ECSW) is a safe, effective and non-invasive new method for the treatment of cardiovascular diseases. The current results show that extracorporeal cardiac shock wave provides a new treatment option for patients with severe and advanced coronary heart disease. However, there are relatively few clinical studies on the application of in vitro cardiac shock waves in patients with myocardial ischemia-reperfusion injury. We hypothesized that extracorporeal cardiac shock therapy would also be effective in reducing clinical endpoints in patients with STEMI reperfusion. This study is order to provide a new therapeutic method for patients with myocardial ischemia-reperfusion injury and reveal the possible mechanism of ECSW for ischemia-reperfusion injury. CEECSWIIRI is a single-center, prospective randomized controlled trial that plans to enroll 102 eligible patients with acute ST-segment elevation myocardial infarction reperfusion. Eligible patients with STEMI reperfusion will be randomly divided into external cardiac shock therapy (ECSW) trial group and blank control group. The blank control group will receive optimal drug therapy, and the experimental group will receive optimal drug therapy combined with ECSW. The shock wave treatment plan will be 3-month therapy, specifically 1 week of treatment per month, 3 weeks of rest, 3 times of ECSW in each treatment week, respectively on the first day, the third day and the fifth day of the treatment week, lasting for 3 months and follow-up for 2 years. The primary endpoint will be to assess the 2-year improvement in all-cause death, re-hospitalization due to cardiovascular disease, major unintentional cerebrovascular events, including cardiogenic death, myocardial infarction, heart failure, arrhythmia, emergency coronary revascularization, and stroke in patients with STEMI reperfusion. Secondary endpoints will include improvements in angina pectoris, quality of life, cardiac structure and function, coronary microcirculation, and endothelial progenitor cell-derived miR-140-3p in relation to survival outcomes. ClinicalTrial.gov.org PRS:NCT05624203; Date of registration: November 12, 2022.